Nutriband Inc. Announces Preferred Stock Dividend Ahead of Key FDA Decision

Nutriband Inc. (NASDAQ: NTRB) has announced the record and payment dates for its 25% preferred stock dividend, a strategic move that highlights the company's focus on enhancing shareholder value and its optimistic outlook towards the FDA approval of its AVERSA Fentanyl product. Shareholders recorded by July 25, 2025, will be entitled to one preferred share for every four common shares they hold, with the dividend distribution scheduled for August 5, 2025. This initiative not only serves as a reward for current shareholders but also ties their potential gains directly to the company's success in navigating the regulatory landscape for its innovative product.

The preferred shares issued under this dividend plan carry the option to convert into common shares upon the FDA's approval of the AVERSA Fentanyl product, a critical juncture for Nutriband Inc. Furthermore, preferred shares that remain unconverted will be eligible for annual cash dividends, contingent upon the company's profitability and the board's discretion. This dual benefit structure is designed to align the interests of the shareholders with the company's long-term growth and success.

At the heart of this development is the AVERSA technology, a proprietary innovation by Nutriband aimed at mitigating the risks of abuse, misuse, diversion, and accidental exposure associated with drugs that have a potential for abuse. This technology represents a significant leap forward in the field of transdermal pharmaceutical products, offering a safer alternative for the delivery of potent medications. The dividend announcement, therefore, not only underscores the company's confidence in its product pipeline but also reinforces its commitment to addressing critical challenges in drug safety and abuse prevention.

For more information on the AVERSA technology and its potential impact on the pharmaceutical industry, visit https://ibn.fm/wfve0. This dividend strategy by Nutriband Inc. is a testament to the company's innovative approach to both product development and shareholder engagement, setting a precedent for how biotech firms can align their financial strategies with their mission to advance healthcare solutions.